Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Banxia Xiexin Decoction in Gastric Cancer
NCT05908838Phase 1Completed
- Sponsor
- Shuguang Hospital
- Start
- Jan 2017
- Primary completion
- Dec 2022
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
Phase 1, randomised, double-blind trial of Jiawei Banxia Xiexin Tang in gastric cancer (GC), sponsored by Shuguang Hospital. Primary endpoint: Overall Survival at 18 weeks. Started Jan 2017; status: completed.
02
Drugs
Jiawei Banxia Xiexin Tang
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05908838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908838.